ICAAC 2007

A Smart + Strong Site
Subscribe to:
POZ magazine
IAS 2007 47th Interscience Conference
on Antimicrobial Agents and Chemotherapy
September 17-20, 2007

September 21, 2007
48-Week Selzentry Data Show Promise for Drug-Resistant HIV
Forty-eight weeks of therapy with Selzentry, combined with an optimized background regimen (OBR), is associated with greater viral load reductions and CD4 count increases compared with placebo among HIV-positive patients with limited treatment options due to drug resistance.
September 20, 2007
Selzentry Treatment Failure: The Impact of Tropism Changes
Approximately two thirds of patients participating in Phase III studies of Pfizer’s Selzentry (maraviroc) who experience treatment failure have HIV that has switched its tropism—a shift in the cellular receptors it uses to infect CD4s.
September 18, 2007
Prezista Shows Well in Patients New to Treatment
Prezista may be approved only for treatment-experienced patients, but new data suggest that it may have a lot to offer treatment newbies as well. 
September 17, 2007
Lexiva and Kaletra Comparable in Long-Term Study
New data reported at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago suggest that Norvir (ritonavir)-boosted Lexiva (fosamprenavir) is similar to Kaletra (ritonavir-boosted lopinavir) in terms of long-term safety and effectiveness.

September 24, 2007
Etravirine for NNRTI-Resistant HIV: Pooled DUET Study Results
A combined analysis of two Phase III clinical trials of etravirine suggests that the drug is promising for treatment-experienced patients, when combined with an optimized background regimen (OBR).
September 21, 2007
Single-Dose PRO 140 Has Lasting Effects
Researchers once again reported promising results from an early study of PRO 140, an experimental HIV entry inhibitor.
September 20, 2007
Two-Year Vicriviroc Benefit in Treatment-Experienced Patients
Schering-Plough’s vicriviroc may offer long-lasting viral load reductions in treatment-experienced patients who combine the drug with an optimized background regimen (OBR). 
September 19, 2007
IL-2 May Delay Need for Antiretroviral Treatment
An intriguing study suggests that periodic injections with interleukin-2 (IL-2) may allow HIV-positive patients to keep their CD4 counts high and postpone their need to begin antiretroviral therapy.
Elvitegravir Study Highlights Value of Strong Background Regimen
Like all other promising experimental drugs, Gilead’s elvitegravir needs to be combined with other active drugs to which HIV is sensitive. 
September 18, 2007
Isentress Offers Long-Term Benefits for Drug-Resistant Patients
New follow-up data from a Phase II clinical trial evaluating Merck's integrase inhibitor Isentress suggests that the drug may offer long-term benefits to HIV-positive people with extensive treatment experience and drug resistance.

September 18, 2007
Heart Disease Risk Remains in Absence of HIV Treatment
There is growing evidence to suggest that untreated HIV infection may be a bigger threat to heart health than the lipid-raising effects of antiretroviral therapy. New data reported at the 47th ICAAC may explain help explain why this is.
September 17, 2007
High Risk of Peripheral Artery Disease in HIV
Not only do HIV-positive people face an increased risk of heart attacks and strokes due to clogging of the major blood vessels, but they may also be more likely to suffer from peripheral artery disease (PAD), which can affect other parts of the body.

September 20, 2007
Wisdom for Women: An Expert's Take on HIV and Gender Differences
Peter Staley asks Dr. Sharon Walmsley what women need to know about HIV and antivirals, and gender differences needing more research.
September 19, 2007
Coming Down the Pike: Expanding HIV Treatment Options
Peter Staley asks Dr. Joe Eron about the latest data on soon-to-be-approved Isentress and an entry inhibitor you might inject just once every other week.
New Data Explores Current Treatment Options
Peter Staley asks Dr. Joe Eron about the good news on a challenging drug -- newly-approved Selzentry -- and the very potent new protease inhibitor, Prezista.
September 18, 2007
Secrets of a Long-Term Survivor
Peter Staley talks with Matt Sharp about his activism, his new regimen, and his facial lipo fix.
Interview with a Hep C Activist & Survivor
Peter Staley interviews Jules Levin, an activist and survivor of hepatitis C and HIV coinfection, about the latest in HCV treatment and prevention.


Our ICAAC conference coverage was generously sponsored by Abbott Laboratories and Merck.

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.